MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务。

Crenolanib

CAS No. : 670220-88-9

MCE 站：Crenolanib

产品活性：Crenolanib 是有效和选择性的野生型和突变型 III 类受体酪氨酸激酶抑制剂，抑制 FLT3 和 PDGFRα/β 的 K_d 分别为 0.74 nM，2.1 nM，3.2 nM。

研究领域：Protein Tyrosine Kinase/RTK  |  Autophagy

作用靶点：FLT3  |  PDGFR  |  Autophagy

In Vitro: Crenolanib has 25-fold more affinity for PDGFRA/B compared with KIT, ａnd is approximately 135-fold more potent than STI571 for inhibiting the PDGFRA D842V mutation. The IC₅₀ for crenolanib for a KIT exon 11 deletion mutant kinase is greater than 1,000 versus 8 nM for STI571. Crenolanib has low nanomolar potency against the V561D + D842V-mutant kinase that is similar to its potency against the isolated D842V mutation. Both STI571 ａnd crenolanib potently inhibit the kinase activity of the fusion oncogene with IC₅₀ values of 1 ａnd 21 nM, respectively, ａnd inhibits PDGFRA activation in this cell line with IC₅₀ values of 93 ａnd 26 nM, respectively. HL60/VCR ａnd K562/ABCB1 cells, overexpressing ABCB1, are 6.9- ａnd 3.6-fold resistant to crenolanib, respectively, in relation to parental HL60 ａnd K562 cells. PSC-833 fully reverses resistance to crenolanib in both HL60/VCR ａnd K562/ABCB1 cells. Crenolanib (1 nM-10 μM) stimulates ABCB1 ATPase activity in a concentration-dependent manner. Crenolanib treatment does not increase the cell surface expression of ABCB₁. Crenolanib inhibits [¹²⁵I]-IAAP photocrosslinking of ABCB1 at high concentrations, with 50 % inhibition at 10 μM, but has little effect at lower concentrations, below 1 μM. Crenolanib decreases NSCLC cell viability, induces apoptosis in NSCLC cells, ａnd inhibits cell migration in NSCLC cells.

In Vivo: Crenolanib (10 mg/kg ａnd 20 mg/kg) suppresses non-small-cell lung cancer tumor growth in vivo ａnd induces tumor cell apoptosis, ａnd the dosage of crenolanib applied is well tolerated by recipient mice.

相关产品：Drug Repurposing Compound Library Plus  |  Clinical Compound Library Plus  |  Bioactive Compound Library Plus  |  Kinase Inhibitor Library  |  Protein Tyrosine Kinase Compound Library  |  Anti-Cancer Compound Library  |  Clinical Compound Library  |  Autophagy Compound Library  |  Anti-Aging Compound Library  |  Drug Repurposing Compound Library  |  Reprogramming Compound Library  |  Anti-COVID-19 Compound Library  |  Anti-Lung Cancer Compound Library  |  Anti-Blood Cancer Compound Library  |  Sunitinib  |  Imatinib  |  SU 5402  |  Cediranib  |  AT9283  |  Gandotinib  |  KW-2449  |  Lestaurtinib  |  CG-806  |  AST 487  |  Ki20227  |  SU14813  |  PP121  |  Sennoside B  |  PP58  |  AG 1295  |  JNJ-47117096 hydrochloride  |  Methylnissolin  |  BPR1J-097 Hydrochloride  |  Crotonoside  |  SU16f  |  Trapidil  |  Tyrosine kinase-IN-1  |  SKLB4771  |  Tyrphostin AG1296  |  Tyrphostin AG1433  |  NVP-ACC789  |  PD-161570

品牌介绍:
•   MCE (MedChemExpress) 拥有数百种全球独家化合物，我们致力于为全球科研客户提供*新*全的高品质小分子活性化合物；
•   10,000 多种高选择性抑制剂、激动剂涉及各热门信号通路及疾病领域；
•   设有专业的实验中心和严格的质控、验证体系；
•   提供 LC/MS、NMR、HPLC、手性分析、元素分析等各项质检报告，确保产品的高纯度、高品质；
•   产品的生物活性多经各国客户实验验证；
•   Nature, Cell, Science 等多种期刊及制药收录了MCE客户的科研成果；
•   专业团队跟踪*新的制药及生命科学研究进展，为您提供全球*新的活性化合物；
•   与世界各大制药公司及知名科研机构建立了长期的合作。